Physical activity in patients with haemophilia - advantages and prophylaxis. Current trends
DOI:
https://doi.org/10.12775/QS.2025.41.60057Keywords
hemophilia, prophylaxis, physical activity, gene therapy, hemophilic arthropathyAbstract
Hemophilia is the most prevalent severe hereditary hemorrhagic disorder. Severe hemophilia symptoms encompass recurrent joint bleeding that can result in degenerative arthropathy. The manifestation of hemophilic arthropathy symptoms markedly diminishes the quality of life for affected patients and considerably restricts their social functioning. The approach to treating hemophilia has been transformed, focusing on preventing hemophilic arthropathy and helping patients lead normal lives alongside healthy individuals. Historically, involvement in sports was discouraged because to the elevated chance of injury and subsequent hemorrhaging; however, contemporary medical understanding advocates for sports engagement to enhance physical and social well-being. Prophylaxis effectively sustains a minimum level of clotting factor activity, enabling people with hemophilia to engage regularly in sports activities.
Aim of the study: The fundamental objective of this research is to clarify the latest management concepts related to hemophilia. Considerable emphasis is placed on the significance and safety of physical activity for persons affected by this disease.
Materials and methods: A review of the literature available in the PubMed and Google Scholar database was performed, using the key words: “hemophilia”, “prophylaxis”, “physical activity”, “gene therapy”, “hemophilic arthropathy”.
Conclusion: Advancements in treatment have increased the life expectancy of those with hemophilia, and the need to optimize health is underscored through preventing chronic conditions and promoting regular physical activity. Recent evidence indicates that physical activity is advantageous and safe in this condition. Additional study is required to formulate specific suggestions for patient education and enhance their long-term quality of life.
References
[1] Rodríguez-Merchán EC, De Pablo-Moreno JA, Liras A. Gene therapy in hemophilia: Recent advances. Int J Mol Sci 2021;22. https://doi.org/10.3390/ijms22147647.
[2] Mannucci PM. Hemophilia treatment innovation: 50 years of progress and more to come. Journal of Thrombosis and Haemostasis 2023;21:403–12. https://doi.org/10.1016/j.jtha.2022.12.029.
[3] Benemei S, Boni L, Castaman G. Outcome measures in hemophilia: current and future perspectives. Expert Rev Hematol 2024;17:329–40. https://doi.org/10.1080/17474086.2024.2365929.
[4] Green D. Hemophilia and Other Congenital Coagulopathies in Women. J Hematol 2024;13:137–41. https://doi.org/10.14740/jh1298.
[5] Cnossen MH, van Moort I, Reitsma SH, de Maat MPM, Schutgens REG, Urbanus RT, et al. SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders. Journal of Thrombosis and Haemostasis 2022;20:2001–11. https://doi.org/10.1111/jth.15778.
[6] Castaman G, Peyvandi F, De Cristofaro R, Pollio B, Di Minno DMN. Mild and Moderate Hemophilia A: Neglected Conditions, Still with Unmet Needs. J Clin Med 2023;12. https://doi.org/10.3390/jcm12041368.
[7] Mancuso ME, Bidlingmaier C, Mahlangu JN, Carcao M, Tosetto A, Kurnik K, et al. The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH. Journal of Thrombosis and Haemostasis 2018;16:2106–10. https://doi.org/10.1111/jth.14257.
[8] Kessi EMCJ, Maslouhi K, Guelzim Y, Belkouchi L, Allali N, Chat L, et al. Severe Hemophilic Arthropathy of the Knee: MRI Has Its Place. Glob Pediatr Health 2024;11. https://doi.org/10.1177/2333794X241280116.
[9] Dimple Choudhry Sudhir S. Effect of Exercise on Muscle Strength, Pain and Functional Ability in Patients with Haemophilia: A Narrative Review. International Journal of Science and Research (IJSR) 2024;13:238–42. https://doi.org/10.21275/sr24101122713.
[10] Valentino LA, Santaella ME, Carlson SA, Recht M. Contemporary approaches to treat people with hemophilia: what’s new and what’s not? Res Pract Thromb Haemost 2025;9. https://doi.org/10.1016/j.rpth.2025.102696.
[11] Wang X, Li Z, Li L. The hemophilia quality of life scale: a systematic review. Front Public Health 2024;12. https://doi.org/10.3389/fpubh.2024.1294188.
[12] Kotsiou N, Evangelidis P, Bolios M, Tragiannidis K, Kalmoukos P, Ntova Z, et al. Quality-of-Life Assessment and Pharmacokinetic Study in Hemophilia A Patients Undergoing Prophylactic Treatment. Pharmacy 2025;13:16. https://doi.org/10.3390/pharmacy13010016.
[13] Alcedo Andrade PE, Mannucci PM, Kessler CM. Emicizumab: the hemophilia A game-changer. Haematologica 2024;109:1334–47. https://doi.org/10.3324/haematol.2022.282099.
[14] Lenting PJ, Fong S. Gene therapy for hemophilia. Blood Adv 2024;8:6081–6081. https://doi.org/10.1182/bloodadvances.2024013864.
[15] Ucero-Lozano R, Pérez-Llanes R, Cuesta-Barriuso R, Donoso-Úbeda E. Changes in Quality of Life, Adherence, and Kinesiophobia in Patients with Hemophilia Treated with Extended Half-Life Treatment: Final Results of the LongHest Project. Pharmaceuticals 2024;17. https://doi.org/10.3390/ph17070835.
[16] Wagner B, Krüger S, Hilberg T, Ay C, Hasenoehrl T, Huber DFX, et al. The effect of resistance exercise on strength and safety outcome for people with haemophilia: A systematic review. Haemophilia 2020;26:200–15. https://doi.org/10.1111/hae.13938.
[17] Wagner B, Seuser A, Krüger S, Herzig ML, Hilberg T, Ay C, et al. Establishing an online physical exercise program for people with hemophilia. Wien Klin Wochenschr 2019;131:558–66. https://doi.org/10.1007/s00508-019-01548-1.
[18] Wilding J, Zourikian N, Di Minno M, Khair K, Marquardt N, Benson G, et al. Obesity in the global haemophilia population: prevalence, implications and expert opinions for weight management. Obesity Reviews 2018;19:1569–84. https://doi.org/10.1111/obr.12746.
[19] Kahan S, Cuker A, Kushner RF, Maahs J, Recht M, Wadden T, et al. Prevalence and impact of obesity in people with haemophilia: Review of literature and expert discussion around implementing weight management guidelines. Haemophilia 2017;23:812–20. https://doi.org/10.1111/hae.13291.
[20] Ransmann P, Hmida J, Brühl M, Schildberg FA, Goldmann G, Oldenburg J, et al. The influence of severity of hemophilia on bone mineral density and fracture risk. Res Pract Thromb Haemost 2024;8. https://doi.org/10.1016/j.rpth.2024.102624.
[21] Goto M, Takedani H, Yokota K, Haga N. Strategies to encourage physical activity in patients with hemophilia to improve quality of life. J Blood Med 2016;7:85–98. https://doi.org/10.2147/JBM.S84848.
[22] Visweshwar N, Zhang Y, Joseph H, Jaglal M, Ayala I. Chronic pain in patients with hemophilia: Is it preventable? Blood Coagulation and Fibrinolysis 2020;31:346–52. https://doi.org/10.1097/MBC.0000000000000939.
[23] Tomschi F, Ransmann P, Hilberg T. Aerobic exercise in patients with haemophilia: A systematic review on safety, feasibility and health effects. Haemophilia 2022;28:397–408. https://doi.org/10.1111/hae.14522.
[24] Pinelli E, Valdrè L, Piscitelli L, Senesi G, Scoppolini Massini M, Guarino V, et al. Improving functional capacity in haemophilia through adapted physical activity: a pilot study protocol. BMJ Open Sport Exerc Med 2025;11. https://doi.org/10.1136/bmjsem-2025-002494.
[25] Howell C, Scott K, Patel DR. Sports participation recommendations for patients with bleeding disorders. Transl Pediatr 2017;6:174–80. https://doi.org/10.21037/tp.2017.04.07.
[26] Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020;26:1–158. https://doi.org/10.1111/hae.14046.
[27] Biasoli C, Baldacci E, Coppola A, De Cristofaro R, Di Minno MND, Lassandro G, et al. Promoting physical activity in people with haemophilia: the MEMO (Movement for persons with haEMOphilia) expert consensus project Recommendation HAEMOSTASIS AND THROMBOSIS. Blood Transfus 2022;20:66–77. https://doi.org/10.2450/2021.0138-20.
[28] Versloot O, Timmer MA, de Kleijn P, Schuuring M, van Koppenhagen CF, van der Net J, et al. Sports participation and sports injuries in Dutch boys with haemophilia. Scand J Med Sci Sports 2020;30:1256–64. https://doi.org/10.1111/sms.13666.
[29] Chimeno-Hernández A, Querol-Giner F, Pérez-Alenda S, Núñez-Cortés R, Cruz-Montecinos C, Carrasco JJ, et al. Effectiveness of physical exercise on postural balance in patients with haemophilia: A systematic review. Haemophilia 2022;28:409–21. https://doi.org/10.1111/hae.14556.
[30] Haghpanah S, Naderi M, Kamalian S, Tavoosi H, Parand S, Javanmardi N, et al. The impact of inhibitors on the quality of life in patients with hemophilia. SAGE Open Med 2023;11. https://doi.org/10.1177/20503121231182284.
[31] Wilczyński B, Juszczyk D, Zorena K, Mital A. Strength training program for an athlete with hemophilia A and an inhibitor while taking a new prophylactic drug treatment: a case report. Physiother Theory Pract 2023;39:2470–8. https://doi.org/10.1080/09593985.2022.2070886.
[32] Azab AR, Elnaggar RK, Aloraini GS, Aldhafian OR, Alshahrani NN, Kamel FAH, et al. Adolescents with hemophilic knee arthropathy can improve their gait characteristics, functional ability, and physical activity level through kinect-based virtual reality: A randomized clinical trial. Heliyon 2024;10. https://doi.org/10.1016/j.heliyon.2024.e28113.
[33] Moretti L, Bizzoca D, Buono C, Ladogana T, Albano F, Moretti B. Sports and children with hemophilia: Current trends. Children 2021;8. https://doi.org/10.3390/children8111064.
[34] National Bleeding Disorders Foundation. Steps for Living. Available online: https://stepsforliving.hemophilia.org/ (accessed on 4 April 2025).
[35] Ai D, Huang K, Li G, Zhen Y, Wu X, Zhang N, et al. Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A. Front Pediatr 2022;10. https://doi.org/10.3389/fped.2022.1045070.
[36] Tomschi F, Hmida J, Herzig S, Ransmann P, Brühl M, Schmidt A, et al. Physical activity and factor VIII levels in patients with haemophilia: A real-world prospective observational study. Haemophilia 2024;30:419–25. https://doi.org/10.1111/hae.14965.
[37] Ay C, Napolitano M, Hassoun A, Tomic R, Martin C, Seifert W, et al. Classification of recombinant factor VIII products and implications for clinical practice: A systematic literature review. Haemophilia 2024;30:577–88. https://doi.org/10.1111/hae.15001.
[38] Srichumpuang C, Rakmanotham A, Moonla C, Sosothikul D. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis. Orphanet J Rare Dis 2024;19. https://doi.org/10.1186/s13023-024-03092-2.
[39] Marchesini E, Morfini M, Valentino L. Recent advances in the treatment of hemophilia: A review. Biologics 2021;15:221–35. https://doi.org/10.2147/BTT.S252580.
[40] Pipe SW, Trzaskoma B, Minhas M, Lehle M, Ko RH, Gao L, et al. Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis. Res Pract Thromb Haemost 2023;7. https://doi.org/10.1016/j.rpth.2023.100077.
[41] Nogami K, Fujii T, Sawada A, Nagao A, Nagae C, Nojima M, et al. Association of physical activity with bleeding events and safety in patients with haemophilia A starting emicizumab prophylaxis: an interim analysis of the TSUBASA study. Int J Hematol 2024;119:14–23. https://doi.org/10.1007/s12185-023-03679-8.
[42] Teranishi-Ikawa Y, Soeda T, Koga H, Yamaguchi K, Kato K, Esaki K, et al. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state. Journal of Thrombosis and Haemostasis 2024;22:430–40. https://doi.org/10.1016/j.jtha.2023.09.034.
[43] Lentz SR, Chowdary P, Gil L, Lopez-Jaime FJ, Mahlangu J, Matytsina I, et al. FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. Journal of Thrombosis and Haemostasis 2024;22:990–1000. https://doi.org/10.1016/j.jtha.2023.12.016.
[44] Escobar M, Bullano M, Mokdad AG, Caicedo J, Schultz BG, Fan Q, et al. A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors. Expert Rev Hematol 2023;16:467–74. https://doi.org/10.1080/17474086.2023.2198207.
[45] Garcia J, Hammer MR, Zia A. Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis. Res Pract Thromb Haemost 2023;7. https://doi.org/10.1016/j.rpth.2023.102238.
[46] Pasca S. Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient’s Perspectives. J Blood Med 2022;13:191–9. https://doi.org/10.2147/JBM.S242219.
[47] Young G, Lenting PJ, Croteau SE, Nolan B, Srivastava A. Antithrombin lowering in hemophilia: a closer look at fitusiran. Res Pract Thromb Haemost 2023;7. https://doi.org/10.1016/j.rpth.2023.100179.
[48] Chernyi N, Gavrilova D, Saruhanyan M, Oloruntimehin ES, Karabelsky A, Bezsonov E, et al. Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives. Biomolecules 2024;14. https://doi.org/10.3390/biom14070854.
[49] Cuker A, Kavakli K, Frenzel L, Wang J-D, Astermark J, Cerqueira MH, et al. Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B. N Engl J Med 2024;391:1108–18. https://doi.org/10.1056/NEJMoa2302982.
[50] Nathwani AC. Gene therapy for hemophilia | Gene ther apy for hemophilia. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):569-578. doi: 10.1182/hematology.2022000388.
[51] Tebo C, Gibson C, Mazer-Amirshahi M. Hemophilia and von Willebrand Disease: A Review of Emergency Department Management. Journal of Emergency Medicine 2020;58:756–66. https://doi.org/10.1016/j.jemermed.2020.02.019.
[52] Jiménez-Yuste V, Álvarez-Román MT, Berrueco R, Bonanad S, Calvo-Villas JM, González-González R, et al. Management of Urgent Bleeding in Patients with Hemophilia A: Focus on the Use of Emicizumab. TH Open 2024;08:e194–201. https://doi.org/10.1055/s-0044-1785525.
[53] Gualtierotti R, Tafuri F, Arcudi S, Solimeno PL, Acquati J, Landi L, et al. Current and Emerging Approaches for Pain Management in Hemophilic Arthropathy. Pain Ther 2022;11. https://doi.org/10.1007/s40122-021-00345-x.
[54] Nagao A, Orita S, Fukutake K, Takedani H. Integrating musculoskeletal ultrasound as a shared decision-making tool in hemophilia care: observations from a 3-year study. Res Pract Thromb Haemost 2024;8. https://doi.org/10.1016/j.rpth.2024.102511.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Patrycja Jędrzejewska-Rzezak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 87
Number of citations: 0
